Clinical Trials

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Marginal Zone

NCT03160079 2025-11-10

Blinatumomab & Pembrolizumab for Adults With Relapsed/Refractory B-cell ALL With High Marrow Lymphoblasts

16 enrolled 14 charts

Burkitt Lymphoma, Recurrence

NCT03010176 2025-10-29

MK-1454-001

156 enrolled 20 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Lymphoma

NCT04875195 2025-10-29

MK-3475-B68

66 enrolled 16 charts

Phase 1 Active not recruiting

Hodgkin Disease

NCT03150329 2025-09-03

Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL.

52 enrolled 13 charts

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT03331341 2025-08-05

Doxorubicin Hydrochloride, Pembrolizumab, Vinblastine, and Dacarbazine in Treating Patients With Classical Hodgkin Lymphoma

50 enrolled 10 charts

Hodgkin Disease

NCT03401853 2025-07-22

Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma

Phase 2 Terminated

18 enrolled 14 charts

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT03884556 2025-07-02

TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers

GastrointestinalGenitourinaryLymphoidThoracic

56 enrolled 19 charts

Urinary Bladder Neoplasms, Lung Neoplasms, Lymphoma, Neoplasms, Pancreatic Neoplasms

NCT03598998 2025-06-26

Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas

Phase 1/2 Active not recruiting

13 enrolled 12 charts

DermatologicLymphoid

Subcutaneous panniculitis-like T-cell lymphoma, Immunoblastic Lymphadenopathy, Lymphoma, Follicular, Mycosis Fungoides, Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic, Enteropathy-Associated T-Cell Lymphoma

NCT03035331 2025-05-16

Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma

LymphoidOther hematologic neoplasm

11 enrolled 12 charts

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT03286114 2025-05-11

Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab

Phase 1 Terminated

16 enrolled 13 charts

LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04317066 2025-04-06

KEYNOTE-A33

7 enrolled 13 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Lymphoma, B-Cell

NCT03058289 2025-02-27

IT-01

BreastGastrointestinalHead & NeckLymphoidSarcomaThoracic

111 enrolled 21 charts

Diabetes Mellitus, Insulin-Dependent, 12, Bile Duct Neoplasms, Breast Neoplasms, Carcinoma, Carcinoma, Squamous Cell, Colonic Neoplasms, Head and Neck Neoplasms, Liver Neoplasms, Lung Neoplasms, Lymphoma, Neoplasms, Pancreatic Neoplasms, Sarcoma

NCT03630042 2024-11-07

PembroWM

17 enrolled 7 charts

Waldenstrom Macroglobulinemia, Recurrence

NCT02453594 2024-10-29

Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-087/KEYNOTE-087)

211 enrolled 22 charts

Hodgkin Disease

NCT03340766 2024-10-17

HARBOUR

31 enrolled 29 charts

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT02595866 2024-08-09

Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer

DermatologicGastrointestinalLymphoidSarcomaThoracic

58 enrolled 17 charts

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Non-Hodgkin, Melanoma, Neoplasm Metastasis, Neoplasms, Recurrence, Sarcoma, Kaposi, HIV Infections

NCT02981914 2024-04-22

Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation

Phase EARLY_PHASE1 Completed

12 enrolled 11 charts

LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Lymphoma, B-Cell

NCT02332980 2024-01-03

Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas

LymphoidOther hematologic neoplasm

65 enrolled 21 charts

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT03229278 2023-12-06

Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma

DermatologicGenitourinaryHead & NeckLymphoidThoracic

14 enrolled 13 charts

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Lymphoma, Melanoma, Neoplasm Metastasis

NCT03255018 2023-11-28

Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extranodal Diffuse Large B-cell Lymphomas

12 enrolled 21 charts

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT03063632 2023-10-25

Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma

28 enrolled 15 charts

LymphoidSarcoma

Mycosis Fungoides, Sezary Syndrome, Sarcoma, Synovial, Liposarcoma, Myxoid

NCT03077828 2023-06-02

Pembrolizumab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Phase 2 Unknown

43 enrolled 9 charts

Hodgkin Disease

NCT03776864 2023-05-03

Umbralisib and Pembrolizumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Phase 2 Terminated

6 enrolled 8 charts

Hodgkin Disease

NCT02178722 2022-02-14

Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers